Article

Distribution of Cerebrovascular Phenotypes According to Variants of the ENG and ACVRL1 Genes in Subjects with Hereditary Hemorrhagic Telangiectasia

Eleonora Gaetani 1,2,*, Elisabetta Peppucci 1,3, Fabiana Agostini 1,2, Luigi Di Martino 1,2, Fabiana Agostini 1,2, Luigi Di Martino 1,2, Emanuela Lucci Cordisco 1,4, Carmelo L. Sturiale 1,3, Alfredo Puca 1,3, Angelo Forfidia 1,2, Andrea Alexandre 1,5, and Roberto Pola 1,2

Abstract: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder caused, in more than 80% of cases, by mutations of either the endoglin (ENG) or the activin A receptor-like type 1 (ACVRL1) gene. Several hundred variants have been identified in these HHT-causing genes, including deletions, missense and nonsense mutations, splice defects, duplications, and insertions. In this study, we have analyzed retrospectively collected images of magnetic resonance angiographies (MRA) of the brain of HHT patients, followed at the HHT Center of our University Hospital, and looked for the distribution of cerebrovascular phenotypes according to specific gene variants. We found that cerebrovascular malformations were heterogeneous among HHT patients, with phenotypes that ranged from classical arteriovenous malformations (AVM) to intracranial aneurysms (IA), developmental venous anomalies (DVA), and cavernous angiomas (CA). There was also wide heterogeneity among the variants of the ENG and ACVRL1 genes, which included known pathogenic variants, variants of unknown significance, variants pending classification, and variants which had not been previously reported. The percentage of patients with cerebrovascular malformations was significantly higher among subjects with ENG variants than ACVRL1 variants (25.0% vs. 13.1%, p < 0.05). The prevalence of neurovascular anomalies was different among subjects with different gene variants, with an incidence that ranged from 3.3% among subjects with the c.1231C > T, c.200G > A, or c.1120C > T missense mutations of the ACVRL1 gene, to 75.0% among subjects with the c.1435C > T missense mutation of the ACVRL1 gene. Further studies and larger sample sizes are required to confirm these findings.

Keywords: hereditary hemorrhagic telangiectasia; cerebrovascular malformations; arteriovenous malformations; genetics; gene variants; ENG; ACVRL1

1. Introduction

Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disorder with an estimated prevalence of 1–5 cases/10,000 individuals [1]. The clinical
hallmarks of the disease are multiple arteriovenous shunts, or arteriovenous malformations (AVMs), affecting several organs, including the skin, nasal and oral mucosa, lungs, liver, brain, and gastrointestinal tract [2,3].

Most HHT-causing variants are detected in endoglin (ENG) and activin A receptor type II-like kinase 1 (ALK1/ACVRL1) genes [4–6]. Less than 2% of cases are instead due to variants of the Family Member 4 (SMAD4) gene [7]. Pathogenic variants in the ENG and ACVRL1 genes result in different HHT types, commonly referred to as HHT1 and HHT2, respectively [4,5]. Pathogenic variants in the SMAD4 gene give rise to a combined syndrome of HHT and juvenile polyposis (JP): the JP-HHT syndrome [7]. Several hundred variants of the ENG and ACVRL1 genes, including deletions, duplications, missense and nonsense mutations, splice defects, and silent variants, have been identified in patients with HHT [8,9] and are present in HHT mutation databases (http://arup.utah.edu/database/ENG/ENG_welcome.php, accessed on 7 March 2022) [10]. Whether single gene variants are associated with specific HHT phenotypes is under investigation and remains to be determined, since HHT is a rare disease and many of the above-mentioned gene variants have been reported in the literature only once.

At the level of the central nervous system (CNS), there is a wide spectrum of possible cerebrovascular malformations in HHT. These include AVMs, but also cavernous malformations (CAs), capillary telangiectasias (CTs), developmental venous anomalies (DVAs), arteriovenous fistulas (AVFs), and intracranial aneurysms (IAs) [11,12].

The aim of this study was to assess the distribution of different types of cerebrovascular malformations according to specific variants of the ENG and ACVRL1 genes in subjects with HHT.

2. Materials and Methods

Ethics. This study was approved by the Ethics Committee of the Fondazione Policlinico Universitario A. Gemelli IRCCS (protocol number 6241/20, ID 2999, date of approval 20 February 2020). Due to the retrospective nature of the study, and the fact that the study only consisted of analysis of data available in the electronic database of our hospital, additional informed consent was not required.

Patients. We collected data of patients followed at the HHT Center of the Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy. Only data of patients who had a genetically established diagnosis of HHT and had undergone Magnetic Resonance Imaging of the brain with angiographic study (MRA) were collected.

Review of MRA. MRA images were reviewed by four independent investigators of our HHT Center (two neuroradiologists and two neurosurgeons), blinded to the genotypes of patients. The results of the review were tabulated as follows: negative exam (no evidence of cerebrovascular malformations); positive exams (evidence of at least one of the following cerebrovascular malformations: AVM, CA, CT, DVA, AVF, IA).

Statistical analysis. Results are presented as mean ± SD or number and percentage. Comparisons between groups were made by using Student’s t test. Differences were considered statistically significant for p < 0.05.

3. Results

We identified 77 patients with genetically verified HHT with fully accessible MRA images of the brain, which is part of the screening routinely performed on HHT patients at our center. The demographic, clinical, genetic, and neuroradiological characteristics of these patients are reported in Table 1. Briefly, all patients were Italians of Caucasian ancestry. Mean age was 53.6 ± 16.7 years. Male/female ratio was 33/44. Most patients (98.7%) belonged to a definite HHT family, while only one patient (1.3%) had negative family history. Regarding HHT clinical hallmarks, recurrent epistaxis and cutaneous telangiectasias were present in 94.8% and 90.9% of patients, respectively. Lung and liver involvement was found in 32.5% and 44.1% of patients, respectively. GI bleeding was reported in 24.7% of cases. ENG and ACVRL1 variants were found in 16 (20.8%) and
61 (79.2%) patients, respectively. MRAs were negative for any type of cerebrovascular malformations in 65 patients (84.4%), while they were positive in 12 patients (15.6%), with a male/female ratio of 5/7. There were four patients (three males and one female) with an AVM, three patients (one male and two females) with an IA, one patient (male) with the concomitant presence of an AVM and an IA, two patients (2 females) with a CA, and two patients (two females) with a DVA, for a total of 13 vascular malformations.

Table 1. Characteristics of the study population.

| Characteristics                              | Value                  |
|---------------------------------------------|------------------------|
| Mean age (years ± SD)                       | 53.6 ± 16.7            |
| Gender (male/female ratio)                  | 33/44                  |
| Epistaxis (n/total)                         | 73/77                  |
| Mucocutaneous telangiectases (n/total)      | 70/77                  |
| Family history of HHT (n/total)             | 76/77                  |
| Pulmonary AVMs (n/total)                    | 25/77                  |
| Hepatic AVMs (n/total)                      | 34/77                  |
| Gastrointestinal AVMs (n/total)             | 19/77                  |
| Cerebrovascular malformations (n/total)     |                        |
| - Arteriovenous malformation (AVM)          | 12/77                  |
| - Intracranial aneurysm (IA)                | 4/12                   |
| - Developmental venous anomaly (DVA)        | 3/12                   |
| - Cavernous angioma (CA)                    | 2/12                   |
| - AVM + IA                                  | 2/12                   |
| ENG mutations                               | 16/77                  |
| ACVRL1 mutations                            | 61/77                  |

A schematic representation of the diverse types of cerebrovascular malformations found in our cohort is shown in Figure 1.

Figure 1. Types of cerebrovascular malformations found in our cohort of HHT patients.

Figure 2 presents instead representative MR images of the diverse types of cerebrovascular malformations found in our HHT cohort.
The most represented gene variants in our population were the c.1231C > T (14 patients pending classification, and two were variants not previously reported in the HHT mutation database. Among the known pathogenic variants (which were found in a total of 13 patients), one was a variant of unknown significance (VUS), and eight were variants not previously reported in the HHT mutation database. Among the ACVRL1 variants, 11 were known pathogenic variants (distributed in a total of 45 patients), three were variants pending classification (distributed in a total of three patients), one was a variant of unknown significance (VUS), and eight were variants not previously reported in the HHT mutation database (distributed in a total of 11 patients). The most represented gene variants in our population were the c.1231C > T (14 patients from five unrelated families), the c.200G > A (eight patients from three unrelated families), and the c.1120C > T (eight patients from three unrelated families) missense mutations of the ACVRL1 gene.

Table 2 reports the different gene variants that we found in our cohort. In total, there were 10 ENG variants and 24 ACVRL1 variants. Among the ENG variants, seven were known pathogenic variants (which were found in a total of 13 patients), one was a variant pending classification, and two were variants not previously reported in the HHT mutation database. Among the ACVRL1 variants, 11 were known pathogenic variants (distributed in a total of 45 patients), three were variants pending classification (distributed in a total of three patients), one was a variant of unknown significance (VUS), and eight were variants not previously reported in the HHT mutation database (distributed in a total of 11 patients). The most represented gene variants in our population were the c.1231C > T (14 patients from five unrelated families), the c.200G > A (eight patients from three unrelated families), and the c.1120C > T (eight patients from three unrelated families) missense mutations of the ACVRL1 gene.

Table 3 reports the distribution of cerebrovascular malformations according to ENG and ACVRL1 variants. The percentage of patients with cerebrovascular malformations
was significantly higher among subjects with ENG variants (four out of 16 patients) than among subjects with ACVRL1 variants (eight out of 61 patients) (25.0% vs. 13.1%, respectively, \( p < 0.05 \)). Among the four patients with ENG variants who had cerebrovascular malformations, three were females and one was a male. Among the eight patients with ACVRL1 variants who had cerebrovascular malformations, four were females and four were males. When the correlation analysis was limited to known pathogenic variants, the percentage of patients with cerebrovascular malformations was 23.1% in the ENG group and 11.1% in the ACVRL1 group. As mentioned above, the c.1231C > T, the c.200G > A, and the c.1120C > T missense mutations of the ACVRL1 gene were the most represented variants in our population. Taken together, they were present in 30 patients, i.e., 38.9% of the study population. However, in these 30 patients we found only one cerebrovascular anomaly, with an incidence of 3.3%. On the opposite side, there was the c.1435C > T missense mutation of the ACVRL1 gene that, although present only in four patients, was associated with three cases of cerebrovascular malformations, with an incidence of 75.0%. There was also the c.771dup variant of the ENG gene that, although found only in three patients, was associated with one case of cerebrovascular malformations (incidence 33.3%).

Table 2. Distribution of gene variants.

| Nucleotide Change | Type of Variant | Classification | Patients (n) |
|-------------------|----------------|----------------|-------------|
| ENG               |                |                |             |
| c.771dup         | Duplication    | pathogenic     | 4           |
| c.309_311del      | Deletion       | pathogenic     | 3           |
| c.1678C > T       | Nonsense       | pathogenic     | 2           |
| c.1199delG        | Deletion       | pathogenic     | 1           |
| c.1 A > G         | Missense       | pathogenic     | 1           |
| c.511C > T        | Nonsense       | pathogenic     | 1           |
| c.967_968del      | Deletion       | pathogenic     | 1           |
| c.1088G > A       | Missense       | pending classification | 1 |
| c.582_600del      | deletion       | not previously reported | 1 |
| c.1115T > C       | Missense       | not previously reported | 1 |
| ACVRL1            |                |                |             |
| c.1231C > T       | Missense       | pathogenic     | 14          |
| c.1120C > T       | Missense       | pathogenic     | 8           |
| c.200G > A        | Missense       | pathogenic     | 8           |
| c.1435C > T       | Missense       | pathogenic     | 4           |
| c.430C > T        | Missense       | pathogenic     | 4           |
| c.1121G > A       | Missense       | pathogenic     | 1           |
| c.1135G > A       | Missense       | pathogenic     | 2           |
| c.1232G > A       | Missense       | pathogenic     | 1           |
| c.218_219insAA    | Insertion      | pathogenic     | 1           |
| c.435del          | Deletion       | pathogenic     | 1           |
| c.1435C > T       | Missense       | pathogenic     | 1           |
| c.230G > A        | Missense       | pending classification | 1 |
| c.526G > T        | Missense       | pending classification | 1 |
| c.988G > T        | Missense       | pending classification | 1 |
| c.1445C > A       | Missense       | VUS            | 2           |
| c.264C > G        | Missense       | not previously reported | 2 |
| c.847_853delinsTT | deletion-insertion | not previously reported | 2 |
| c.144_145insG     | Insertion      | not previously reported | 1 |
| c.771_772dup      | Duplication    | not previously reported | 1 |
| c.837C > G        | Missense       | not previously reported | 1 |
| c.1028A > C       | Missense       | not previously reported | 1 |
| c.398C > G        | Missense       | not previously reported | 1 |
| c.915_916dup      | Duplication    | not previously reported | 1 |
| c.738_739dup      | Duplication    | not previously reported | 1 |
Table 3. Distribution of cerebrovascular malformations according to ENG and ACVRL1 variants.

| Nucleotide Change        | Positive/Total MRA | Type of Malformation |
|--------------------------|--------------------|----------------------|
| All ENG variants         | 4/16 (25.0%)       |                      |
| Pathogenic variants      | 3/13 (23.1%)       |                      |
| c.1199delG               | 0/1 (0.0%)         | –                    |
| c.1678C > T              | 1/2 (50.0%)        | AVM                  |
| c.1A > G                 | 1/1 (100.0%)       | IA                   |
| c.309,311del             | 0/3 (0.0%)         | –                    |
| c.511C > T               | 0/1 (0.0%)         | –                    |
| c.771dup                 | 1/4 (25.0%)        | AVM                  |
| c.967,968del             | 0/1 (0.0%)         | –                    |
| Other variants           | 1/3 (33.3%)        |                      |
| c.1115T > C              | 1/1 (100.0%)       | DVA                  |
| c.1088G > A              | 0/1 (0.0%)         | –                    |
| c.582,600del             | 0/1 (0.0%)         | –                    |
| All ACVRL1 variants      | 8/61 (13.1%)       |                      |
| Pathogenic variants      | 5/45 (11.1%)       |                      |
| c.1120C > T              | 0/8 (0.0%)         | –                    |
| c.1121G > A              | 0/1 (0.0%)         | –                    |
| c.1135G > A              | 0/2 (0.0%)         | –                    |
| c.1231C > T              | 1/14 (7.1%)        | CA                   |
| c.1232G > A              | 1/1 (100.0%)       | AVM + IA             |
| c.1435C > T              | 3/4 (75.0%)        | 2 IA (M, F), 1 DVA   |
| c.200G > A               | 0/8 (0.0%)         | –                    |
| c.218,219insAA           | 0/1 (0.0%)         | –                    |
| c.430C > T               | 0/4 (0.0%)         | –                    |
| c.435del                 | 0/1 (0.0%)         | –                    |
| Other variants           | 3/16 (18.7%)       |                      |
| c.230G > A               | 0/1 (0.0%)         | –                    |
| c.526G > T               | 1/1 (100.0%)       | AVM                  |
| c.988G > T               | 0/1 (0.0%)         | –                    |
| c.1445C > A              | 0/2 (0.0%)         | –                    |
| c.144,145insG            | 0/1 (0.0%)         | –                    |
| c.771,772dup             | 1/1 (100.0%)       | CA                   |
| c.837C > G               | 0/1 (0.0%)         | –                    |
| c.1028A > C              | 0/1 (0.0%)         | –                    |
| c.264C > G               | 0/2 (0.0%)         | –                    |
| c.398C > G               | 0/1 (0.0%)         | –                    |
| c.915,916dup             | 1/1 (100.0%)       | AVM                  |
| c.847,853delinsTT        | 0/2 (0.0%)         | –                    |
| c.738,739dup             | 0/1 (0.0%)         | –                    |

4. Discussion

In this study, we evaluated the distribution of cerebrovascular phenotypes according to specific ENG and ACVRL1 gene variants in subjects with HHT. It is interesting to note that, in our population, neurovascular anomalies were significantly more frequent among ENG than ACVRL1 patients. This is consistent with the results of a recent meta-analysis [13], showing that patients with HHT1 have a significantly higher brain AVM prevalence compared with those with HHT2 and confirms that different genetic backgrounds may have an impact on the cerebrovascular phenotypes of HHT patients.

On the other hand, it is also notable that some gene variants, although numerically well represented in our population, were never–or very rarely–associated with the presence of a cerebrovascular malformation. In particular, this was the case of the c.1231C > T, c.200G > A, and c.1120C > T missense mutations of the ACVRL1 gene, which cumulatively were present in 24 patients (35.3% of our population) but were associated with a cerebrovascular malformation only in one case. It is also interesting that, among HHT2 patients, a consistent proportion of cerebrovascular malformations (37.5%) was found in patients carrying gene variants for which an established pathogenic role does not exist yet, according to the HHT
Mutation Database [10]. Indeed, in this study, we found nine novel variants which had never been reported previously. One of these was a deletion (c.582_600del) detected in the ENG gene in one patient who did not have any cerebrovascular malformation at MRA of the brain. The other eight variants which had never been reported before were in the ACVRL1 gene and were found in a total of 10 patients. Additional studies will be important for establishing whether the relationship between these variants and cerebrovascular malformations are common or coincidental occurrences.

This study also constitutes a useful report on the incidence of cerebrovascular malformations in HHT, which was 15.6% in our population. This incidence is similar to that reported by Woodall and coll. in 2014 (18.6%) and Brinjikji and coll. in 2016 [11,14]. It is instead higher than that reported by Maher and coll. in 2001 (3.7%) [15], but it should be noted that this study took into account patients who were not screened for the presence of a cerebral vascular malformation, while our study only included subjects for whom neurovascular imaging was available. Regarding the type of malformation, our study confirms that vascular brain lesions are heterogeneous among HHT patients. AVMs were the most common in our population, with an incidence of 6.5%. IAs were also common, with an incidence of 5.2%. The notion that HHT patients often have aneurysmatic diseases has been recently confirmed by a retrospective analysis of Ring and coll., who found 43 patients with at least one aneurysm on 418 HHT subjects, with a prevalence of 10.3% [16]. Taken together, IAs and AVMs accounted for 75.0% of all cerebrovascular malformations. The remaining malformations were CAs (two cases, with an incidence of 2.6% in the study population), and DVAs (one case, with an incidence of 1.3% in the study population).

This study has potential limitations. First, the sample size is small, and many gene variants are presented only in single patients. This certainly hinders the possibility to evaluate whether an association exists between these variants and specific cerebrovascular malformations. Additionally, it is known that the rupture of cerebrovascular malformations is devastating in the HHT pediatric population [17,18]. Since our study only includes adult individuals, it might be limited by a survival bias. Additionally, we have been able to analyze only those patients with genetically confirmed HHT who had undergone MRA. Therefore, our sample is not representative of the general HHT population. In addition, since the gold standard for the diagnosis of arteriovenous shunts is catheter angiography and we only had access to MRA data, the incidence of AVFs and microscopic AVMs might be underestimated.

In summary, this study provides updated information on the incidence and distribution of cerebrovascular malformations according to specific gene variants in subjects with HHT. Further studies are needed to substantiate these findings and potentially lead to personalization of risk stratification and screening regimens for cerebrovascular malformations in HHT patients.

Author Contributions: Conceptualization, E.P., F.A., R.P.; methodology, E.G., L.D.M., A.P. (Angelo Porfidia); formal analysis, E.G., E.P., R.P.; investigation, E.G., E.P., F.A., L.D.M., E.L.C., C.L.S., A.P. (Alfredo Puca), A.P. (Angelo Porfidia), A.A., A.P. (Alessandro Pedicelli), R.P.; data curation, E.P., L.D.M., F.A.; writing—original draft preparation, E.G., E.P., R.P.; writing—review and editing, E.G., L.D.M., A.A., R.P.; supervision, E.G., R.P.; project administration, E.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Fondazione Policlinico Universitario A. Gemelli IRCCS (protocol number 6241/20, ID 2999, date of approval 20 February 2020).

Informed Consent Statement: Due to the retrospective nature of the study, and the fact that the study only consisted in analysis of data available in the electronic database of our hospital, informed consent was not required.

Data Availability Statement: Data are available upon request to the corresponding author.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Faughnan, M.E.; Mager, J.J.; Hetts, S.W.; Palda, V.A.; Lang-Robertson, K.; Buscarini, E.; Deslandres, E.; Kasthuri, R.S.; Lausman, A.; Poetker, D.; et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Amn. Intern. Med. 2020, 173, 989–1001. [CrossRef] [PubMed]

2. Shovlin, C.L.; Buscarini, E.; Kjeldsen, A.D.; Mager, H.J.; Sabba, C.; Droege, F.; Geisthoff, U.; Ugolini, S.; Dupuis-Girod, S. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J. Rare Dis. 2018, 13, 136. [CrossRef] [PubMed]

3. McDonald, J.; Bayrak-Toydemir, P.; Pyeritz, R.E. Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis. Genet. Med. 2011, 13, 607–616. [CrossRef] [PubMed]

4. McAllister, K.A.; Grogg, K.M.; Johnson, D.W.; Gallione, C.J.; Baldwin, M.A.; Jackson, C.E.; Helmbold, E.A.; Markel, D.S.; McKinnon, W.C.; Murrell, J.; et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8, 345. [CrossRef] [PubMed]

5. Johnson, D.W.; Berg, J.N.; Baldwin, M.A.; Gallione, C.J.; Marondel, I.; Yoon, S.J.; Stenzel, T.T.; Speer, M.; Pericak-Vance, M.A.; Diamond, A.; et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 1996, 13, 189. [CrossRef] [PubMed]

6. McDonald, J.; Wooderchak-Donahue, W.; VanSant Webb, C.; Whitehead, K.; Stevenson, D.A.; Bayrak-Toydemir, P. Hereditary hemorrhagic telangiectasia: Genetics and molecular diagnostics in a new era. Front. Genet. 2015, 6, 1. [CrossRef]

7. Gallione, C.J.; Repetto, G.M.; Legius, E.; Rustgi, A.K.; Schelley, S.L.; Tejpar, S.; Mitchell, G.; Drouin, É.; Westermann, C.J.; Marchuk, D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363, 852–859. [CrossRef]

8. Albiñana, V.; Zafra, M.P.; Colau, J.; Zarrabeitia, R.; Recio-Poveda, L.; Olavarrieta, L.; Pérez-Pérez, J.; Botella, L.M. Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1. BMC Med. Genet. 2017, 18, 20. [CrossRef]

9. Gallione, C.J.; Repetto, G.M.; Legius, E.; Rustgi, A.K.; Schelley, S.L.; Tejpar, S.; Mitchell, G.; Drouin, É.; Westermann, C.J.; Marchuk, D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363, 852–859. [CrossRef]

10. Available online: http://arup.utah.edu/database/ENG/ENG_welcome.php (accessed on 7 March 2022).

11. Woodall, M.N.; McGettigan, M.; Figueroa, R.; Gossage, J.R.; Alleyne, C.H., Jr. Cerebral vascular manifestations in hereditary hemorrhagic telangiectasia. J. Neurosurg. 2014, 120, 87–92. [CrossRef]

12. Krings, T.; Kim, H.; Power, S.; Nelson, J.; Faughnan, M.E.; Young, W.L.; terBrugge, K.G.; THE Brain Vascular Malformations HHT Investigation Group. Neurovascular Manifestation in Hereditary Hemorrhagic Telangiectasia: Imaging Features and Genotype-Phenotype Correlations. AJNR Am. J. Neuroradiol. 2015, 36, 863–870. [CrossRef] [PubMed]

13. Brinjikji, W.; Yer, V.N.; Wood, C.P.; Lanzino, G. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: A systematic review and meta-analysis. J. Neurosurg. 2017, 127, 302–310. [CrossRef] [PubMed]

14. Poetker, D.; et al. RiHHTa Investigators of the Rare Disease Working Group from the Spanish Society of Internal Medicine. Current HHT Genetic Overview in Spain and its phenotypic Correlation: Data from RiHHTa registry. Orphanet J. Rare Dis. 2020, 15, 138. [CrossRef] [PubMed]

15. Available online: http://arup.utah.edu/database/ENG/ENG_welcome.php (accessed on 7 March 2022).

16. Woodall, M.N.; McGettigan, M.; Figueroa, R.; Gossage, J.R.; Alleyne, C.H., Jr. Cerebral vascular manifestations in hereditary hemorrhagic telangiectasia. J. Neurosurg. 2014, 120, 87–92. [CrossRef]

17. McDonald, J.; Wooderchak-Donahue, W.; VanSant Webb, C.; Whitehead, K.; Stevenson, D.A.; Bayrak-Toydemir, P. Hereditary hemorrhagic telangiectasia: Genetics and molecular diagnostics in a new era. Front. Genet. 2015, 6, 1. [CrossRef]

18. Gallione, C.J.; Repetto, G.M.; Legius, E.; Rustgi, A.K.; Schelley, S.L.; Tejpar, S.; Mitchell, G.; Drouin, É.; Westermann, C.J.; Marchuk, D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363, 852–859. [CrossRef]

19. Sánchez-Martínez, R.; Iriarte, A.; Mora-Luján, J.M.; Patier, J.L.; López-Wolf, D.; Ójeda, A.; Torralba, M.A.; Juyol, M.C.; Gil, R.; Anon, S.; et al. RiHHTa Investigators of the Rare Disease Working Group from the Spanish Society of Internal Medicine. Current HHT Genetic Overview in Spain and its phenotypic Correlation: Data from RiHHTa registry. Orphanet J. Rare Dis. 2020, 15, 138. [CrossRef] [PubMed]

20. Available online: http://arup.utah.edu/database/ENG/ENG_welcome.php (accessed on 7 March 2022).

21. Woodall, M.N.; McGettigan, M.; Figueroa, R.; Gossage, J.R.; Alleyne, C.H., Jr. Cerebral vascular manifestations in hereditary hemorrhagic telangiectasia. J. Neurosurg. 2014, 120, 87–92. [CrossRef]

22. Brinjikji, W.; Iyer, V.N.; Wood, C.P.; Lanzino, G. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: A systematic review and meta-analysis. J. Neurosurg. 2017, 127, 302–310. [CrossRef] [PubMed]

23. Brinjikji, W.; Iyer, V.N.; Yamaki, V.; Lanzino, G.; Cloft, H.J.; Thielen, K.S.; Swanson, K.L.; Wood, C.P. Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years. Am. J. Neuroradiol. 2016, 37, 1479–1486. [CrossRef] [PubMed]

24. Maher, C.O.; Piepgras, D.G.; Brown, D., Jr.; Friedman, J.A.; Pollock, B.E. Cerebrovascular malformations in 321 cases of Hereditary Hemorrhagic Telangiectasia. Stroke 2001, 32, 877–882. [CrossRef]

25. Ring, N.Y.; Latif, M.A.; Hafezi-Nejad, N.; Holly, B.P.; Weiss, C.R. Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-Year Retrospective Series of 418 Patients. J. Vasc. Interv. Radiol. 2021, 32, 1661–1669. [CrossRef]

26. Morgan, T.; McDonald, J.; Anderson, C.; Ismail, M.; Miller, F.; Mao, R.; Madan, A.; Barnes, P.; Hodgins, L.; Manning, M. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). Pediatrics 2002, 109, e12. [CrossRef]

27. Kilian, A.; Latino, G.A.; White, A.; Clark, D.; Chakinala, M.M.; Ratjen, F.; McDonald, J.; Whitehead, K.; Gossage, J.R.; the Brain Vascular Malformation Consortium HHT Investigator Group; et al. Genotype-phenotype Correlations in Children with HHT. J. Clin. Med. 2020, 9, 2714. [CrossRef] [PubMed]